AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9

Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or ...

New to The Street’s Esteemed Client Laser Photonics Closes $4 Million Private Placement

NEW YORK CITY, NEW YORK / ACCESS Newswire / October 1, 2025 / Laser Photonics Corporation (NASDAQ:LASE) (“LPC” or the “Company”), a global leader in industrial laser systems for cleaning and other ...

Engage2Excel and American Greetings Team Up to Bring More Recognition and Smiles to the Workplace

MOORESVILLE, NORTH CAROLINA / ACCESS Newswire / October 1, 2025 / Engage2Excel, a leader in recruitment, recognition and ...

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment ...

Detailed price information for Cellectar Biosciences Inc (CLRB-Q) from The Globe and Mail including charting and trades.